Composition for regulating emotion as well as preparation method and application thereof

Abstract

The invention provides a composition for regulating emotion as well as a preparation method and application thereof, and belongs to the technical field of nutritional compositions. The composition for regulating emotion provided by the invention comprises the following components in parts by weight: 1-3 parts of cannabidiol and 1-3 parts of cannabinoid phenol. Animal tests show that the composition has the function of relieving anxious mood and depressive mood caused by pressure.

Description

Technical Field

[0001] The invention belongs to the technical field of nutritional compositions and relates to a composition for regulating mood and a preparation method and application thereof. Background Art

[0002] Cannabis sativa L. is an annual herbaceous plant of the Cannabaceae family and the Cannabis genus. Cannabis contains more than 100 terpenoid bioactive substances, namely cannabinoids. Among them, cannabidiol (CBD) and cannabigerol (CBG) are two important components.

[0003] The molecular formula of cannabidiol (CBD) is as follows:

[0004]

[0005] The molecular formula of cannabigerol (CBG) is as follows:

[0006]

[0007] Chinese patent application 202180047443.4 provides a composition and method for treating chronic pain. The pharmaceutical composition comprises the following ingredients: i) ≥40% w / w of Δ 9 - tetrahydrocannabinol (THC), ii) ≤ 50% w / w cannabidiol (CBD), iii) ≥ 0.15% w / w cannabigerol (CBG), iv) ≤ 0.5% w / w dehydrocannabidiol (Cannabinodiol, CBN); and (b) a terpene component, the terpene component comprising: i) β-caryophyllene, the amount of β-caryophyllene is ≥ 0.4% w / w of the composition, ii) d-limonene, the amount of d-limonene is ≥ 0.2% w / w of the composition, and iii) β-pinene, the amount of β-pinene is ≥ 0.15% w / w of the composition.

[0008] However, it is difficult in the prior art to provide a composition with a simple formula and a better effect of relieving anxiety and depression caused by external pressure. Summary of the invention

[0009] In view of this, in view of the problem that it is difficult in the prior art to provide a composition with a simple formula and a better effect of relieving anxiety and depression caused by external pressure, the purpose of the present invention is to provide a composition for regulating emotions and its preparation method and application.

[0010] To achieve the above-mentioned purpose of the invention, on the one hand, the present invention provides a composition for regulating mood, which comprises the following ingredients by weight: 1-3 parts of cannabidiol and 1-3 parts of cannabigerol.

[0011] Preferably, the composition comprises the following ingredients by weight: 1-3 parts of cannabidiol and 1 part of cannabigerol.

[0012] More preferably, and as an embodiment of the present invention, the composition comprises the following ingredients by weight: 1 part of cannabidiol and 1 part of cannabigerol.

[0013] On the other hand, the present invention provides a method for preparing the above composition, comprising the following steps: mixing the composition with a solvent, and dissolving the mixture to obtain the composition.

[0014] In yet another aspect, the present invention provides a product for regulating mood, wherein the effective ingredient of the product is the above-mentioned composition or the composition prepared by the above-mentioned preparation method.

[0015] Preferably, the product is selected from at least one of food, health products, nutritional products, and nutritional supplements.

[0016] More preferably, the dosage form of the product is selected from granules, tablets, powders, pastes, solutions, and lozenges.

[0017] In yet another aspect, the present invention provides use of the above composition or the composition prepared by the above preparation method in preparing a product for regulating mood.

[0018] Preferably, the emotion regulation is to relieve anxiety.

[0019] Preferably, the mood regulation is to relieve depression.

[0020] Preferably, the emotion regulation is to relieve the emotion caused by external pressure.

[0021] More preferably, the emotion caused by external pressure is stress emotion.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] (1) The present invention provides a composition for regulating mood with a simple formula, which is expected to be applied in the fields of food, health care products and medicine.

[0024] (2) Animal experiments show that the mood regulating composition provided by the present invention can significantly alleviate the anxiety and depression-like behaviors of mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 It is a bar graph of the time mice spend in the middle area of ​​the open field.

[0026] Figure 2 It is a bar graph of the distance moved by mice in the open field.

[0027] Figure 3Histogram of the number of times mice entered the middle area of ​​the open field.

[0028] Figure 4 is a bar graph of the time mice stayed in the open arms.

[0029] Figure 5 It is a bar graph of the time mice spend immobile in the elevated maze.

[0030] Figure 6 It is a bar graph of the time mice stay in the light box.

[0031] Figure 7 It is a bar graph of the time when the mouse first entered the dark chamber from the light chamber.

[0032] Figure 8 It is a bar graph of the number of times mice crossed the light and dark boxes.

[0033] Fig. 9 It is a bar graph of the immobility time of mice during tail suspension. DETAILED DESCRIPTION

[0034] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.

[0035] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.

[0036] Some of the raw materials used in the present invention come from the following sources:

[0037] name source Cannabidiol BOD Science Cannabigerol BOD Science

[0038] Example 1

[0039] 1 part by mass of cannabidiol and 1 part by mass of cannabigerol.

[0040] Effect evaluation

[0041] 1. Experimental Methods

[0042] 1.1. Experimental Materials

[0043] The following experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Institute of Brain Cognition and Brain Disorders (BCBDI), Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, with the ethics number SIAT-IACUC-20211222-NS-NTPZX-WLP-A2090-01.

[0044] Seven-week-old adult C57BL / 6J male mice used in the following experiments were purchased from Vitallife.

[0045] Experimental design

[0046] After one week of environmental adaptation, 30 adult male C57BL / 6 mice in each batch were given samples of a single component or different formulations by long-term oral gavage for 5 weeks. Then, in the fourth week of sampling, the mice were subjected to 1 week of stress induction, and the blank control group was not given samples and stress induction. Finally, behavioral tests (including anxiety-like behavioral tests and depression-like behavioral tests) were performed, and the mice were continuously sampled during the above-mentioned evaluation experiments.

[0047] The mouse intervention dose was converted based on the human intervention dose, using the body surface area method. Based on the principle that the intervention dose per kilogram of body weight per square meter of body surface area is equal, the mouse dose is 12.3 times that of an adult. The dosage of CBD and CBG in adults is 150 mg / day, and the average adult weight is about 70 kg, so the CBD and CBG doses for mice are 25 mg / kg / d and 25 mg / kg / d, respectively.

[0048] According to the above principles, the dosage was determined. The components or compositions involved in each group in the experiment were as follows:

[0049] Blank control group: intragastric administration of normal saline;

[0050] Model group: intragastric administration of normal saline;

[0051] CBD model group: intragastrically administered 25 mg / kg / d cannabidiol (CBD);

[0052] CBG model group: intragastrically administered 25 mg / kg / d cannabinoids (CBG);

[0053] Group 1 of Example 1: intragastric administration of 50 mg / kg / d of the composition of Example 1.

[0054] The stress response program is as follows:

[0055] Plantar stimulation was performed 10 times (current 0.5 mA, each time lasting 2 seconds, with an interval of 10 seconds); tail suspension was performed for 30 minutes; restraint was performed for 1 hour.

[0056] During the week of stress induction, the above stress regimen was performed once a day in a random order.

[0057] 1.3. Anxiety-like behavior test

[0058] 1.3.1. Open field test

[0059] The open field consists of a square box (35cm×35cm×30cm), which is divided into 16 areas (8.75cm×8.75cm), and the 4 areas in the middle will be defined as the middle area (17.5cm×17.5cm). Mice will be randomly placed in the middle area of ​​the open field. After 10 minutes of exploration, the time the mice stay in the middle area will be recorded and used as an indicator of anxiety. The longer the time spent in the middle area, the lower the anxiety level of the mice.

[0060] 1.3.2. Elevated maze test

[0061] The elevated maze apparatus is a cross-shaped maze with two open arms (35cm×5cm×15cm) and two closed arms (35cm×5cm). The middle area of ​​the cross maze is a fully open area (5cm×5cm). The entire cross maze is 50cm above the ground. At the beginning of the experiment, the mice were placed in the middle area of ​​the maze, facing the open arms. Then, the number of times the mice entered the open arms and closed arms within 7 minutes, the time they stayed in the open arms and closed arms, and the time they were still were automatically monitored. The time the mice stayed in the open arms was used as an anxiety indicator. The longer the mice stayed in the open arms, the lower their anxiety level.

[0062] 1.3.3. Light and dark box test

[0063] The size of the light-dark box device is 50cm×25cm×25cm, which contains two spaces, a light box and a dark box. The partition wall between the two boxes has a 7.5cm×7.5cm door hole for mice to shuttle through. The test time for each mouse is 5min. At the beginning of the test, the mouse is placed in the light box and allowed to explore freely in the device. The time the mouse stays in the light box, the number of times the light and dark boxes shuttle, and the time of the first entry into the dark room are monitored. The time spent in the light box is used as an anxiety indicator. The longer the mouse stays in the light box, the lower the anxiety level.

[0064] 1.4. Depression-like behavior test (tail suspension test)

[0065] The tail suspension test is widely used to assess despair behavior in rodents. Briefly, mice are suspended by tape about 1 cm from the tip of the tail 30 cm above the ground. The duration of the experiment is 6 min, and the immobility time (no struggling, little body movement) during the suspension process is automatically monitored during the last 5 min. The duration of immobility of mice will be used as an indicator of depression, and the longer the immobility time, the higher the degree of depression of the mice.

[0066] Statistical analysis

[0067] Statistical analysis was performed using Prism software. In the behavioral experimental results, each group was first checked for outliers, and significance analysis was performed after elimination. The blank control group and the model group used an unpaired t-test, while the model group and each embodiment group used a one-way anova. Since animals have individual differences in their resistance to stress and behavior, it is necessary to comprehensively evaluate the individual's anxiety and depression levels by combining multiple behavioral tests. The Z-score method was used to normalize the behavioral results and compare them, and finally the efficacy of each intervention group was ranked. Taking the open field experiment as an example, the Z-score calculation formula is as follows:

[0068]

[0069] in,

[0070] X: observed values ​​of behavioral indices of mice in the intervention group;

[0071] μ: mean values ​​of behavioral indicators of mice in the model group;

[0072] σ: standard deviation of behavioral indicators of mice in the model group;

[0073] TC: specifically refers to the time that mice stayed in the open area in the open field test for all parameters in the previous brackets;

[0074] DR: All parameters in the previous brackets are the ratio of the exploration distance of mice in the middle area to the total exploration distance in the open field test;

[0075] Number of parameters: number of parameters.

[0076] Then the elevated maze behavior Z EPM Scoring, light-dark box behavior Z LDB Scoring and tail suspension test Z TST score, due to the anxiety-like behavior Z score (such as Z OF , Z EPM , Z LDB) indicates that the individual has a lower risk of anxiety; in addition, a higher Z score for depression-like behavior indicates that the individual has a higher risk of depression. A The score is the weighted average of the Z scores of each behavior, that is, Z A =(Z OF +Z EPM +Z LDB ) / 3. The overall anxiety and depression behavior is Z T The score is the sum of the anxiety behavior Z score minus the depression behavior Z score. TST The mean after scoring, i.e. Z T =(Z OF +Z EPM +Z LDB -Z TST ) / 4.

[0077] 2. Experimental results

[0078] 2.1. Effects of stress on anxiety-like behavior in mice

[0079] 2.1.1. Open field test

[0080] The results of the open field test are as follows Figure 1 , Figure 2 and Figure 3 Compared with the CBD model group and the CBG model group, the composition of Example 1 group has significantly better effects on increasing the time mice stay in the open field, increasing the distance mice move in the open field, and increasing the number of times mice enter the middle area of ​​the open field. The above results show that the composition provided by the present invention can significantly improve the anxiety-like behavior of mice in the open field.

[0081] 2.1.2. Elevated maze test

[0082] The results of the elevated maze test are as follows Figure 4 , 5 As shown. Compared with the CBD model group and the CBG model group, the composition of Example 1 group has a significantly better effect of increasing the time mice stay in the open arm and reducing the immobility time in the maze. This shows that the composition provided by the present invention can significantly alleviate the anxiety-like behavior of mice in the elevated maze.

[0083] 2.1.3. Light-dark box experiment

[0084] The experimental results of the light-dark box experiment are as follows Figure 6-8 As shown. Compared with the CBD model group and the CBG model group, the composition of Example 1 group has significantly better effects on increasing the time mice stay in the light box, increasing the time mice enter the dark room from the light room for the first time, and increasing the number of times mice pass through the light box. This shows that the composition provided by the present invention can significantly alleviate the anxiety-like behavior of mice in the light and dark boxes.

[0085] 2.2. Effects of stress on depressive-like behavior in mice

[0086] The results of the mouse tail suspension experiment are as follows Fig. 9 The results of the mouse tail suspension experiment showed that compared with the CBD model group and the CBG model group, the composition of Example 1 group had a significantly better effect of reducing the immobility time of mice. This shows that the composition provided by the present invention can significantly alleviate the depressive-like behavior of mice during the tail suspension process.

[0087] 2.3 Comparison of behavioral Z scores

[0088] The anxiety-like behavior Z score of each animal in each group of experiments A and anxiety-depression behavior overall Z score T The scores are shown in the following table:

[0089]

[0090] From the above table, it can be seen that the score table shows that the Z of the Example 1 group A and Z T The average scores of the two groups were higher than those of the CBD model group and the CBG model group. A The scores were the mean of this experiment, and the percentage of individuals with scores higher than the mean was statistically analyzed. The results showed that the CBD model group had 33.3% (3 / 9), the CBG model group had 40% (4 / 10), and the Example 1 group had 50% (5 / 10), indicating that the Example 1 group performed best in the anxiety-like behavior Z score, followed by the CBG group, and finally the CBD group; based on the Z T The scores were the mean of this experiment, and the percentage of individuals with scores above the mean was statistically analyzed. The results showed that the CBD model group had 66.67% (6 / 9), the CBG model group had 40% (4 / 10), and the Example 1 group had 50% (5 / 10), indicating that the CBD model group and the Example 1 group performed similarly in the overall behavioral Z score, and better than the CBG model group.

[0091] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A composition for regulating mood, characterized in that: The following ingredients are included by weight: 1-3 parts of cannabidiol and 1-3 parts of cannabigerol.

2. The composition according to claim 1, characterized in that The following ingredients are included by weight: 1-3 parts of cannabidiol and 1 part of cannabigerol.

3. The composition according to claim 1, characterized in that The following ingredients are included by weight: 1 part cannabidiol and 1 part cannabigerol.

4. A method for preparing a composition according to any one of claims 1 to 3, characterized in that: The following steps are involved: The composition is mixed with a solvent and dissolved to obtain the product.

5. A product for regulating emotions, characterized in that: The active ingredient comprises the composition according to any one of claims 1 to 3 or the composition prepared by the preparation method according to claim 4.

6. The product according to claim 5, characterized in that The product is selected from at least one of food, health care products, nutritional products, and nutritional supplements.

7. Use of the composition according to any one of claims 1 to 3 or the composition prepared by the preparation method according to claim 4 in preparing a product for regulating mood.

8. The use according to claim 7, characterized in that: The described emotion regulation is to relieve anxiety.

9. The use according to claim 7, characterized in that: The mood regulation is to relieve depression.

10. The use according to claim 7, characterized in that: The emotion regulation is to relieve the emotions caused by external pressure.

Images